ArticleEndocrine2026
Clinical and genetic characteristics of patients with complete androgen insensitivity syndrome: an experience from a tertiary care centre of Kashmir Valley.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeComplete Androgen Insensitivity Syndrome (CAIS) is a rare X-linked disorder caused by pathogenic variants in the androgen receptor (AR) gene, leading to resistance to androgens in individuals with a 46, XY karyotype. MATERIALS AND
methodsThis study aims to describe the clinical and genetic profile of CAIS patients from a tertiary care hospital in northern India. Thirteen consecutive patients with a clinical diagnosis of CAIS evaluated at our centre between August 2013 to May 2025 were included. The evaluation included detailed clinical assessment, hormonal evaluation and genetic analysis. Genetic analysis was performed by using a customized next-generation sequencing panel that included AR gene and nine other genes including WNT4, SRD5A2, CYP21A2, POR, HSD17B3, NR5A1, CYP17A1, SOX9, and CYP11B1. The panel covered whole genes including non-coding regions (splice-site and introns).
resultsTen patients presented at puberty with primary amenorrhea and three patients presented in the pre-pubertal period with bilateral inguinal hernias and phenotypically female external genitalia. Pathogenic or likely pathogenic AR variants were identified in 10 of 13 (76.9%) patients. These include likely three novel variants (missense variant c.2198 A > G; in-frame long deletion c.403_1420delGCGG and splice-site deletion c.1616+3_1616 + 6delAAGT) and two known variants (frameshift insertion c.239_240insGCAGCAGC and canonical splice-site variant c. 2608-1G > T). Notably, 7 of the 10 variants were splice-site variants.
conclusionThis is the largest study of CAIS patients from India. The main contribution of our study is the detection of likely three novel and two known pathogenic variants of AR gene associated with CAIS in a Kashmiri cohort. The high frequency of splice-site variants highlights the need to include non-coding regions in the analysis of AR gene for accurate molecular diagnosis.
Indexed as
Identifiers
42545618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.